Molecular Breeding
Our molecular breeding program utilizes a proprietary genomic probe to characterize botanical cultivars, isolate novel therapeutic compounds, and develop targeted Active Pharmaceutical Ingredients (APIs).
Genomic Probe
We utilize a proprietary genomic probe to identify and isolate specific genetic markers responsible for targeted therapeutic production, enabling precise, data-driven trait selection.
Genetic Library
Our genetic library contains over 300 fully sequenced, genotyped, and phenotyped cultivars, providing the foundational dataset for our AI-driven drug discovery models.
Bioengineering
We develop bioengineered constructs to amplify the production of minor therapeutic compounds, transforming trace compounds into scalable, commercially viable APIs.
Advanced Tissue Culture
We utilize advanced tissue culture techniques to generate stable botanical lines, achieving genetic uniformity. This process ensures absolute batch-to-batch consistency in API production, meeting the stringent requirements for FDA clinical trials.
DUS Standards
Achieving Distinctness, Uniformity, and Stability (DUS) to meet USDA and UPOV criteria for plant variety protection.
Defensible IP
Creating a robust intellectual property moat through utility patents and breeders' rights on our proprietary genetics.
Capabilities
We aim to accelerate clinical development by pairing our novel botanical APIs with established delivery technologies. This strategy leverages known safety profiles to reduce clinical risk and expedite time to market.
Proven Safety Profiles
Utilizing delivery systems with established safety data reduces clinical risk.
Accelerated Timeline
Bypassing early-stage formulation challenges to reach clinical milestones faster.
